Advertisement
UK markets closed
  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     
  • HANG SENG

    17,763.03
    +16.12 (+0.09%)
     
  • CRUDE OIL

    79.13
    +0.13 (+0.16%)
     
  • GOLD FUTURES

    2,330.20
    +27.30 (+1.19%)
     
  • DOW

    37,903.29
    +87.37 (+0.23%)
     
  • Bitcoin GBP

    46,170.21
    -1,826.42 (-3.81%)
     
  • CMC Crypto 200

    1,202.07
    -136.99 (-10.23%)
     
  • NASDAQ Composite

    15,605.48
    -52.34 (-0.33%)
     
  • UK FTSE All Share

    4,418.60
    -11.65 (-0.26%)
     

Better Buy: AbbVie vs. Johnson & Johnson

Better Buy: AbbVie vs. Johnson & Johnson

AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. After all, these stocks offer a track record of earnings growth and dividend increases. The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year.